Reckitt's blockbuster deal is a high-risk play

Reckitt's blockbuster deal is a high-risk play

Scepticism is festering among some market watchers about the merits of consumer giant Reckitt Benckiser's (RB.) mooted $16.7bn (£13.5bn) takeover of infant formula business Mead Johnson.

To continue reading, register today

to enjoy limited access to the following:

  • Daily trading news
  • Funds coverage
  • Features on big investment themes
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Related topics

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now